LLY earnings — 2026-08-05

News coverage shows Eli Lilly's second-quarter 2026 print had already landed by the time of tonight's pull. Reuters (July 31) reported Lilly beat estimates on resilient demand for its GLP-1 drugs Mounjaro and Zepbound, widening its lead over Novo Nordisk. MarketBeat (August 4) said shares rose after the strong second-quarter report and an increase to Lilly's 2026 revenue outlook, with Mounjaro/Zepbound demand cited as the central driver. Neither source gives quantified revenue or EPS figures.

The coverage points to the print landing around July 29-31, not August 5 — this event's date reflects the desk's calendar cache, which doesn't match the reporting above; flagged here rather than treated as confirmation the report happened today. No filed quarter is available yet from the desk's financial sources to confirm exact actuals.